Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glesatinib - Mirati Therapeutics

Drug Profile

Glesatinib - Mirati Therapeutics

Alternative Names: MGCD-265

Latest Information Update: 01 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer MethylGene; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c met inhibitors; RON protein inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Jan 2019 Mirati Therapeutics completes a phase I trial in Non-small cell lung cancer, Head and neck cancer and other solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada, South Korea and USA (PO) (NCT00697632)
  • 17 Dec 2018 Glesatinib is available for licensing as of 13 Nov 2017. https://www.mirati.com/
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top